Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 2 | Unknown | PO / MO |
Patient missed the third dose of Vivotif; Case reference number US-BN-2025-001452 is a spontaneous case initially received from a pharmacist via Communications (reference number: USBAV25-2113) on 25-Aug-2025 and concerns a patient of unspecified age and gender. The patient's medical history and concomitant medication details were not provided. On unspecified date, reported as per label, the patient took the first two Vivotif doses (batch number: unknown) at an unknown dose, orally, for typhoid immunization. On 24-Aug-2025, the patient missed the third dose of Vivotif (batch number: unknown) (explicitly coded as 'Product dose omission issue') At the time of initial report, it was unknown if the patient experienced any adverse event due to Vivotif. No further information provided.; Reporter's Comments: This case concerns a patient of unspecified age and gender. As reported, the patient missed the third dose of Vivotif for an indication of typhoid immunization, which is considered as product dose omission issue. Product dose omission issue is considered as listed per company convention. At the time of initial report, it was unknown if the patient experienced any adverse event due to Vivotif. The patient's relevant medical history and concomitant medication details were not provided. Product dose omission issue is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: This case concerns a patient of unspecified age and gender. As reported, the patient missed the third dose of Vivotif for an indication of typhoid immunization, which is considered as product dose omission issue. Product dose omission issue is considered as listed per company convention. At the time of initial report, it was unknown if the patient experienced any adverse event due to Vivotif. The patient's relevant medical history and concomitant medication details were not provided. Product dose omission issue is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None